AZ TO PRESENT NEW DATA AT ADA

ASTRAZENECA TO PRESENT NEW DATA FROM ITS BROAD PORTFOLIO IN WIDE RANGE OF PATIENT POPULATIONS AT THE AMERICAN DIABETES ASSOCIATION 74^TH SCIENTIFIC SESSIONS^®

 

43 abstracts on approved products and an investigational compound accepted for presentation

 

First data from Phase III trial of saxagliptin/dapagliflozin combination presented as a late-breaker

 

First six-year, open-extension to the DURATION-1 trial examining the efficacy and tolerability of exenatide will be presented

 

 

AstraZeneca today announced that 43 abstracts reporting results of the company's research and development in diabetes have been accepted for presentation at the 74^th Scientific Sessions^® of the American Diabetes Association (ADA) in San Francisco, 13-17 June 2014. Clinical data from studies evaluating multiple approved products, including Forxiga^® (dapagliflozin, marketed in the US as Farxiga^™), Bydureon^® (exenatide extended-release for injectable suspension) and Onglyza^® (saxagliptin), as well as the investigational combination of saxagliptin and dapagliflozin, demonstrate AstraZeneca's continued commitment to addressing unmet medical needs across a wide spectrum of type 2 diabetes patients in different stages of the disease. 

 

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "The robust scientific data that will be presented at ADA further strengthen our broad innovative portfolio that spans the entire spectrum of non-insulin anti-diabetic treatments. Our continued focus on advancing scientific knowledge reinforces our long-term commitment to diabetes, a core strategic area for us and an important platform for returning AstraZeneca to growth."

                                                                                                                                  

"Diabetes is a progressive and complex disease which demands combination approaches to further improve patient care," said Briggs Morrison, MD, Executive Vice President, Global Medicines Development & Chief Medical Officer, AstraZeneca. "Our data accepted for presentation at this year's ADA, including trials evaluating our medicines in patients with significant comorbidities and in combination with other anti-diabetic agents, reflect AstraZeneca's efforts to provide these treatment options that address the needs of patients at different stages of the disease."

 

Notable data on an AstraZeneca investigational compound at ADA include:

·     A late-breaker of the first presentation of Phase III data evaluating the investigational combination of saxagliptin/dapagliflozin as a dual add-on therapy in adult patients with type 2 diabetes who were inadequately controlled on metformin,  the top-line results of which were announced in May. Results being presented at ADA, and published in the abstract available in Diabetes, include secondary outcome measures on body weight and efficacy. (#127-LB, Sunday, 15 June, 12:00 PM PDT)^[i]

 

Notable data on approved AstraZeneca products at ADA include:

·     An analysis from nine double-blind, placebo-controlled trials evaluating the safety of dapagliflozin in elderly patients (#269-OR, Monday, 16 June, 9:30 AM PDT)[ii]

·     An analysis from three randomised controlled trials examining the effect of exenatide extended-release for injectable suspension on daily blood glucose variability compared with basal insulin (#997-P, Saturday, 14 June, 11:30 AM PDT)[iii]

·     A sub-group analysis from the SAVOR trial examining the effect of saxagliptin on renal outcomes (#544-P, Saturday, 14 June, 11:30 AM PDT)[iv]

·     An analysis from two double-blind, placebo-controlled trials evaluating the effects of dapagliflozin on systolic blood pressure (#1033-P, Sunday, 15 June, 12:00 PM PDT)[v]

·     A sub-group analysis from the SAVOR trial examining the effect of saxagliptin in elderly patients from the study population (#1057-P, Sunday, 15 June, 12:00 PM PDT)[vi]

·     An open-ended extension to the DURATION-1 trial examining the efficacy and tolerability of exenatide once-weekly over six years (#964-P, Saturday, 14 June, 11:30 AM PDT)[vii]

·     An analysis from five placebo-controlled trials examining the effects of saxagliptin on β-cell function in patients with latent autoimmune diabetes (#152-OR, Sunday, 15 June, 8:45 AM PDT)[viii]

 

The complete list of AstraZeneca data presentations can be accessed on the ADA website here.

 

 

CONTACTS

 

Media Enquiries

Esra Erkal-Paler                          +44 20 7604 8030 (UK/Global)

Vanessa Rhodes                         +44 20 7604 8037 (UK/Global)

Ayesha Bharmal                          +44 20 7604 8034 (UK/Global)

Jacob Lund                                  +46 8 553 260 20 (Sweden)

Michele Meixell                            + 1 302 885 6351 (US)

 

Investor Enquiries

Karl Hård                                    +44 20 7604 8123  mob: +44 7789 654364

Colleen Proctor                           + 1 302 886 1842     mob:  +1 302 357 4882

Anthony Brown                            +44 20 7604 8067    mob: +44 7585 404943

Jens Lindberg                             +44 20 7604 8414    mob: +44 7557 319729